Freedom from progression (FFP) by adding paclitaxel (T) to doxorubicin (A) followed by CMF as adjuvant or primary systemic therapy: 10-yr results of a randomized phase III European Cooperative Trial in Operable Breast Cancer (ECTO).
Milvia Zambetti
No relevant relationships to disclose
José Baselga
No relevant relationships to disclose
Wolfgang Eiermann
Consultant or Advisory Role - Roche
Honoraria - Roche
Vicente Guillem
No relevant relationships to disclose
Vladimir Semiglazov
No relevant relationships to disclose
Ana Lluch
No relevant relationships to disclose
Dolores Sabadell
No relevant relationships to disclose
Alla Bozhok
No relevant relationships to disclose
Mikhail J. Byakhov
No relevant relationships to disclose
Belen Ojeda
No relevant relationships to disclose
Mauro Mansutti
No relevant relationships to disclose
Gabriella Mariani
No relevant relationships to disclose
Angela Moliterni
No relevant relationships to disclose
Hernan Cortes-Funes
No relevant relationships to disclose
Marian Colozza
No relevant relationships to disclose
Tadeusz Pienkowski
No relevant relationships to disclose
Domenico Magazzu
No relevant relationships to disclose
Pinuccia Valagussa
No relevant relationships to disclose
Gianni Bonadonna
No relevant relationships to disclose
Luca Gianni
Consultant or Advisory Role - AstraZeneca (U); Boehringer Ingelheim (U); Celgene (U); GlaxoSmithKline (U); Novartis (U); Pfizer (U); Roche/Genentech